Oragenics, Inc. is a biopharmaceutical company. The Company develops, markets and sells oral cavity probiotics products for humans and pets, under the brand names Evora and ProBiora. The Company is developing its antibiotic product candidate, MU1140, as well as other homolog antibiotic product candidates, researching Live Biotherapeutic Products (LBPs), commercializing its ProBiora3 probiotic products and has other product candidates, including SMaRT Replacement Therapy positioned for out licensing or partnering. MU1140 is an antibiotic that is active against all Gram positive bacteria. ProBiora3 is a blend of three naturally occurring strains of beneficial bacteria, including Streptococcus oralis KJ3, Streptococcus uberis KJ2 and Streptococcus rattus JH145, which promotes fresher breath, whiter teeth and supports overall oral health. LPT3-04 is a natural occurring dietary substance that supports weight loss in overweight men and women.